Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-11
2009-08-18
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S211000
Reexamination Certificate
active
07576106
ABSTRACT:
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
REFERENCES:
patent: 4853384 (1989-08-01), Helsley et al.
patent: 6043257 (2000-03-01), Dominguez et al.
patent: 2004/0014783 (2004-01-01), Rigby et al.
patent: 2004/0259914 (2004-12-01), Ko et al.
patent: 2005/0070609 (2005-03-01), Finke et al.
patent: 2005/0143372 (2005-06-01), Ghosh et al.
patent: 2007/0088036 (2007-04-01), Zhang et al.
patent: 2001019672 (2001-01-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 01/90101 (2001-11-01), None
patent: WO 03/000688 (2003-01-01), None
patent: WO 03/013526 (2003-02-01), None
patent: WO 03/037274 (2003-05-01), None
patent: WO 03/105853 (2003-12-01), None
patent: WO 2004/009550 (2004-01-01), None
patent: WO 2004/054974 (2004-07-01), None
patent: WO 2006/066948 (2006-06-01), None
Xie, et. al. “Identification of novel series of human CCR1 antagonists,” Bioorganic & Medicinal Chemistry Letters 2007, doi: 10.1016/j.bmcl.2007.09.068.
Brown et. al. “Novel CCR1 antagonists with improved metabolic stability” Bioorganic & Medicinal Chemistry Letters 2004, 14, 2175-2179.
Dominguez et. al. “Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors.” Bioorganic & Medicinal Chemistry Letters, 1999, 9, 925-930.
De Lucca et. al. “Discovery and Structure-Activity Relationship of N-(Ureidoalkyl)-Benzyl-Piperidines As Potent Small Molecule CC Chemokine Receptor-3 (CCR3) Antagonists” J. Med. Chem. 2002, 45, 3794-3804.
Ng et. al. “Discovery of Novel Non-Peptide CCR1 Receptor Antagonists” J. Med. Chem. 1999, 42, 4680-4694.
International Search Report mailed on Sep. 27, 2007, for PCT Application No. PCT/US06/40014 filed on Oct. 11, 2006, two pages.
Hesselgesser et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor.”J. Biol. Chem., vol. 273, No. 25, pp. 15687-15692, 1998.
Liang et al., “Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1.”J. Biol. Chem., vol. 275, No. 25, pp. 19000-19008, 2000.
Liang et al., “Species Selectivity of a Small Molecule Antagonist for the CCR1 Chemokine Receptor.”Eur. J. Pharmacol., vol. 389, No. 1, pp. 41-49, 2000.
Ng et al., “Discovery of Novel Non-Peptide CCR1 Receptor Antagonists.”J. Med. Chem., vol. 42, No. 22, pp. 4680-4694, 1999.
Chen Wei
Greenman Kevin Lloyd
Li Lianfa
Pennell Andrew M. K.
Sullivan Edward J.
ChemoCentryx, Inc.
Desai Rita J
O'Dell David K
Townsend and Townsend / and Crew LLP
LandOfFree
Piperidine derivatives and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine derivatives and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070557